Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ858MR)

This product GTTS-WQ858MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ858MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10924MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ7249MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ11626MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ9604MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ6760MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ13953MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ14153MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ4635MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW